Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.41 | N/A | -153.09% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.41 | N/A | -153.09% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced during the quarter. They emphasized their commitment to pipeline development without providing future guidance.
Management did not provide specific guidance for the upcoming quarters.
The focus remains on advancing their pipeline despite the EPS miss.
Nektar Therapeutics reported a significant EPS miss, but the stock still rose by 2.24%. This increase may reflect investor optimism about the company's pipeline and future potential, despite the lack of revenue data and guidance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ONEOK INC NEW
Feb 24, 2014